Tetrabenazine was recently approved to treat this disease, functioning by inhibiting VMAT-2. While this disease's mechanism is not fully understood, it is known to result in nuclear inclusion bodies, which may explain the toxicity caused by its chara
Tetrabenazine was recently approved to treat this disease, functioning by inhibiting VMAT-2. While this disease's mechanism is not fully understood, it is known to result in nuclear inclusion bodies, which may explain the toxicity caused by its characteristic protein misfolding. On a larger scale, it damages the striatum in the brain, likely responsible for its symptoms of chorea. Marked by a long CAG repeat on chromosome 4 resulting in a mutant namesake protein, identify this neurodegenerative autosomal dominant disease whose onset comes around age 40.
Tetrabenazine was recently approved to treat this disease, functioning by inhibiting VMAT-2.
{Huntington's} disease [or {Huntington's} chorea]